Mark Neustrom, DO
Allergy & Immunology · Overland Park, KSNPI 1063449288
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 40.5% of the total.
Across 72 payments — averaging $48.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Shire North American Group Inc$900
- AstraZeneca$155
- GSK$153
- Hospira, Inc.$131
- Ionis Pharmaceuticals, Inc.$124
- plus $620 from 16 others
Across 17 payments — averaging $4619.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biocryst Pharmaceuticals, Inc.$39K
- GSK$25K
- Novartis$14K
What the payments were for
- Consulting fees$1,12532%
- Speaking & faculty fees$90026%
- Food & beverage$1,46042%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $1,416 |
| Shire North American Group Inc | 1 | $900 |
| AstraZeneca | 8 | $155 |
| GSK | 8 | $153 |
| Hospira, Inc. | 8 | $131 |
| Ionis Pharmaceuticals, Inc. | 1 | $124 |
| Biocryst US Sales Co., LLC | 7 | $113 |
| Pharming Healthcare, Inc. | 4 | $72 |
| CSL Behring | 2 | $61 |
| Grifols USA, LLC | 2 | $52 |
| Pfizer | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Cycle Pharmaceuticals Inc | 2 | $35 |
| Genentech USA, Inc. | 2 | $32 |
| AbbVie | 1 | $28 |
| Lilly USA, LLC | 1 | $24 |
| Optinose US, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Novartis | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,499 in reported general payments places this provider in the 60th percentile of 33 allergy & immunology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $13,902 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $1,930 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,515 |
| Azelastine Hcl | 15 | $668 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $649 |
| Montelukast Sodium | 33 | $566 |
| Ipratropium Bromide | 14 | $393 |
| Fluticasone Propionate | 16 | $255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $153 | $13,90216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 33 allergy & immunology providers in Kansas.
Other allergy & immunology in Overland Park
- Henry KanarekOverland Park$143K
- Celina BernabeOverland Park$95K
- William LaveryOverland Park$25K
- Sara AzzamOverland Park$19K
- Nguyen TranOverland Park$15K
- Cori PasserOverland Park$14K
- Derrick WardOverland Park$6K
- James SternerOverland Park$3K
- H LevineOverland Park$3K
- Khaled GirgisOverland Park$636
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.